Better Therapeutics, Inc. (BTTX) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 1.69: the stock has moved about 69% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBetter Therapeutics, Inc. (BTTX) trades at $0.0001. Better Therapeutics, Inc. (BTTX) is a biotechnology company focused on developing software-driven prescription digital therapeutics for cardiometabolic diseases. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for BTTX: BTTX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Better Therapeutics, Inc. (BTTX) Healthcare & Pipeline Overview
Better Therapeutics, Inc. is a pioneer in software-driven prescription digital therapeutics, focusing on innovative solutions for managing cardiometabolic diseases, particularly diabetes, through its unique Nutritional Cognitive Behavioral Therapy platform.
What Is the Investment Thesis for BTTX?
The company’s lead product, BT-001, is in advanced stages of development and targets the significant type 2 diabetes market, which affects over 34 million Americans. The integration of Nutritional Cognitive Behavioral Therapy into its PDTs offers a competitive edge, as it addresses behavioral aspects of disease management. Moreover, the ongoing development of BT-002 and BT-003 expands the company's therapeutic portfolio, catering to hypertension and hyperlipidemia, respectively. As healthcare increasingly shifts toward digital solutions, Better Therapeutics stands to benefit from favorable regulatory trends and growing acceptance of digital health interventions. However, investors may want to evaluate potential risks, including regulatory hurdles and market competition, as the company seeks to establish its products in a rapidly evolving landscape.
Based on FMP financials and quantitative analysis
BTTX Key Highlights
Market Cap: $0.00B, indicating a current valuation reflecting early-stage development.
- Beta: 1.69, suggesting higher volatility compared to the market.
- Employee Count: 54, indicating a focused team dedicated to innovation in digital therapeutics.
- No Dividend Yield, reflecting reinvestment of resources into product development.
- Flagship Product: BT-001, targeting the large type 2 diabetes market.
Who Are BTTX's Competitors?
BTTX is benchmarked below against 5 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| NVCR Novocure | $15.20 | +1.74% | $1.77B | — |
| MDRX Veradigm Inc. | $5.00 | 0.00% | $832M | — |
| RMD ResMed Inc. | $222.86 | +1.81% | $32.3B | 94 5-pillar |
| QTEX Inspira Technologies Oxy B.H.N. Ltd. | $1.54 | +40.00% | $47.9M | 44 5-pillar |
| SI SHOULDER INNOVATIONS, INC. | $19.60 | +3.10% | $397M | 32 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BTTX's Key Strengths?
Innovative product pipeline targeting high-prevalence chronic diseases.
- Strong focus on software-driven therapeutic solutions.
- Experienced leadership team with a background in biotechnology and healthcare.
What Are BTTX's Weaknesses?
Limited market presence as a relatively new company.
- Dependence on regulatory approvals for product commercialization.
- No current revenue stream, as products are still in development.
What Are the Key Risks for BTTX?
Financial-distress signal — its Altman Z-Score of -27.28 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory delays that could impact product launch timelines.
- Competition from both established and emerging digital therapeutics companies.
- Market acceptance of digital health solutions may take time.
- Dependence on successful clinical trial outcomes to validate product efficacy.
What Threats Does BTTX Face?
- Intense competition from established pharmaceutical and biotech companies.
- Regulatory challenges that could delay product launches.
- Market acceptance of digital therapeutics is still evolving.
What Are BTTX's Competitive Advantages?
- Innovative use of Nutritional Cognitive Behavioral Therapy sets it apart from traditional treatments.
- Focus on software-driven solutions aligns with the increasing trend toward digital health.
- Strong emphasis on research and development fosters continuous innovation.
- Potential for partnerships with healthcare providers enhances market credibility.
- Targeting high-prevalence chronic diseases provides a large addressable market.
What Does BTTX Do?
Founded in 2015 and headquartered in San Francisco, California, Better Therapeutics, Inc. specializes in the development of software-driven prescription digital therapeutics (PDTs) targeting cardiometabolic conditions. The company was established with the vision of leveraging technology to improve health outcomes in patients suffering from chronic diseases such as diabetes and heart disease. Better Therapeutics has made significant strides in creating its flagship product, BT-001, which utilizes Nutritional Cognitive Behavioral Therapy (NCBT) to help patients manage type 2 diabetes effectively. This innovative approach combines behavioral therapy with nutritional guidance, aiming to empower patients to make sustainable lifestyle changes. In addition to BT-001, the company is advancing its pipeline with BT-002, aimed at assisting patients with hypertension in controlling blood pressure, and BT-003, which focuses on optimizing cholesterol levels for individuals with hyperlipidemia. Better Therapeutics operates primarily in the U.S. market, where the demand for effective digital health solutions is rapidly growing, driven by the increasing prevalence of cardiometabolic diseases. The company's commitment to innovation and patient-centric solutions positions it uniquely in the biotechnology sector, addressing critical health challenges with scalable digital interventions.
What Products and Services Does BTTX Offer?
- Develop software-driven prescription digital therapeutics (PDTs) for chronic diseases.
- Focus on managing cardiometabolic conditions such as diabetes, hypertension, and hyperlipidemia.
- Utilize Nutritional Cognitive Behavioral Therapy (NCBT) in its digital therapeutics.
- Conduct research and development to innovate new therapeutic solutions.
- Engage with healthcare providers to promote digital health solutions.
- Aim to improve patient outcomes through behavioral and lifestyle interventions.
How Does BTTX Make Money?
- Generate revenue through the development and commercialization of prescription digital therapeutics.
- Potential partnerships with healthcare providers and payers for broader market access.
- Focus on subscription-based models for ongoing patient engagement and support.
- Leverage data analytics to enhance product offerings and patient outcomes.
- Seek regulatory approvals to ensure product viability and market entry.
What Industry Does BTTX Operate In?
The biotechnology industry, particularly in the healthcare sector, is witnessing a significant shift towards digital therapeutics, which are projected to grow rapidly as healthcare providers and patients increasingly embrace technology-driven solutions. With the global digital therapeutics market expected to expand at a CAGR of 20% through 2025, companies like Better Therapeutics are well-positioned to capitalize on this trend. The competitive landscape includes a mix of established pharmaceutical companies and innovative startups, all vying to develop effective digital solutions for chronic disease management. Better Therapeutics' focus on cardiometabolic conditions places it in a critical segment of the market, addressing the needs of millions affected by these diseases.
Who Are BTTX's Key Customers?
- Patients suffering from chronic diseases, particularly type 2 diabetes.
- Healthcare providers looking for innovative treatment options.
- Payers and insurance companies interested in cost-effective health solutions.
- Pharmaceutical companies seeking partnerships in digital health.
- Health systems aiming to improve patient management and outcomes.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Insider Activity
12 transactions · 0 purchases, 0 sales, 12 other transactions · 10 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Forward Outlook
Wall Street analysts project Better Therapeutics, Inc. revenue of about $15.3M for fiscal 2026, with EPS near $-0.69.
Earnings Track Record
Better Therapeutics, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 18.4% below estimates on average.
Financial Health
Better Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -27.28 places it in the distress zone, a signal of elevated financial risk.
Company Profile
Better Therapeutics, Inc. operates in the Healthcare sector. It is headquartered in San Francisco, US. BTTX has traded publicly since 2021.
BTTX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
BTTX Latest News
No recent news available for BTTX.
BTTX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BTTX.
Price Targets
Wall Street price target analysis for BTTX.
BTTX MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BTTX; grades run from A+ (80-100) to F (below 30).
Leadership: David Perry
CEO
David Perry has extensive experience in the healthcare and biotechnology sectors, having held various leadership positions in both public and private companies. He has a strong track record in product development and commercialization, with a focus on innovative therapeutic solutions. Perry holds a degree in Biomedical Engineering and has been instrumental in guiding Better Therapeutics since its inception.
Track Record: Under David Perry's leadership, Better Therapeutics has developed its flagship product, BT-001, and expanded its pipeline with additional PDTs. He has successfully navigated the company through early-stage development, positioning it for future growth in the digital therapeutics market.
BTTX OTC Market Information
The OTC Other tier includes companies that do not meet the criteria for higher tiers like OTCQX or OTCQB. These companies may have limited liquidity and disclosure requirements, making them riskier investments compared to those listed on major exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited regulatory oversight compared to companies listed on major exchanges.
- Potential for lower liquidity, leading to price volatility.
- Increased risk of fraud or misrepresentation in financial reporting.
- Verify the company's financial health through available reports.
- Assess the management team's experience and track record.
- Examine the competitive landscape and market positioning.
- Understand the regulatory environment for digital therapeutics.
- Evaluate the product pipeline and development timelines.
- Partnerships with reputable healthcare organizations.
- Transparency in communication and financial reporting.
- Positive feedback from clinical trials or pilot programs.
BTTX Healthcare Stock FAQ
What are the main risks for BTTX?
The primary risks for Better Therapeutics, Inc. include regulatory hurdles that could delay product launches, as well as competition from established companies in the digital therapeutics space.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- The company is in the early stages of development, and financial metrics are limited.